SOURCE: OmniComm Systems, Inc.

OmniComm Systems, Inc.

July 10, 2015 08:00 ET

OmniComm Systems® Announces Reseller Agreement With Tri-I Biotech Shanghai Inc.

Market Leading Life Sciences Consultancy to Resell OmniComm's TrialOne® eSource Solution

FORT LAUDERDALE, FL--(Marketwired - July 10, 2015) - OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology and services, today announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai Inc., a market leading China based consultancy providing high performance informatics solutions to over 1,000 medical and clinical research organizations across China, Hong Kong, Macau and Taiwan.

"We were looking for a partner who has a clinical trial system that manages clinical data and automates the data capture and laboratory processes in Phase I units," said Mr. Michael Lee, general manager at Tri-I Biotech Shanghai Inc. "It is essential that such a system supports both English and Chinese languages and meets the China market requirements. With OmniComm's TrialOne system, we are confident to sell this first class leading product in China to meet our customers' demand to improve phase I study management by ensuring the data quality and process efficiency. This partnership will strengthen our position as a market leading solutions provider for Phase I units in China."

Tri-I works with medical research organizations including the top 50 clinical trial centers in China exclusively on their informatics and clinical data management projects, providing pre-purchase consulting and implementation services. Tri-I also has significant expertise and clients in early phase clinical research, the target market for OmniComm's TrialOne eSource and clinic automation solution.

TrialOne is a comprehensive set of modules that drive efficiencies, reduces timelines and costs through faster and more directed volunteer recruitment, easy to build schedule based workflows, real-time bedside data collection, direct data capture from devices, sample processing automation and modern data processing. The browser-based, tablet compatible system provides an advanced platform for automating your clinic operations, complies with FDA 21 CFR part 11, and supports data standards such as CDISC for faster and easier exporting and reporting of data.

"The partnership with Tri-I allows us to bring our market leading Phase I unit automation solution TrialOne to clinical pharmacology centers and Phase I units across China, with implementation services and after sales support in the local language," says Wolf Ondracek, senior vice president of Academic and Asian Markets at OmniComm. "Tri-I is experienced in implementing Phase I unit automation solutions and related software systems, and has entry into many of the top tier Phase I units in China. We are absolutely thrilled about this strategic partnership. It is an important step in our further advancement into the Chinese market."

Supporting References
TrialOne

ABOUT Tri-I Biotech (Shanghai) Inc.
Tri-I Biotech (Shanghai) Inc. was founded in May, 2008 at the White Cat Technical Park of Shanghai Jiaotong University.

Tri-I is dedicated to accelerating national development in the pharmaceutical and chemical industry by providing total solutions for biological research, pharmaceutical research, materials simulation, clinical test design, data analysis, information management and quality management. Tri-I keeps enlarging its services range, from HTS data analysis to biological knowledge mining, from systems biology based target identification to computer aided drug design, from ADMET prediction to clinical PK/PD research, and many other areas, to match the development issues of the national health and life sciences sector in China.

Tri-I has successfully supported and participated in many conferences and symposia in different areas of life sciences and materials science, and organized many intensive workshops and webinars, such as special course programs in molecular modeling and drug design, all geared towards training professionals in these important sectors, for the benefit of society.

Tri-I's success relies heavily on its highly qualified staff and their seamless teamwork. Over 90% of Tri-I's team members have a master's degree or higher. For more information, visit http://tri-ibiotech.com.cn.

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world's pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.